Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Textual)

v2.4.0.6
Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2012
Segment
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]    
Number of operating business segments   1
Minimum domestic revenue of sublingual buprenorphine formulations   $ 1,000,000,000
Non-cash loss on an increase in the fair value $ 1,955,000